Klabunde T
Sanofi-Aventis Pharma Deutschland GmbH, Science & Medical Affairs, Drug Design, Industriepark Hoechst, Frankfurt am Main, Germany.
Br J Pharmacol. 2007 Sep;152(1):5-7. doi: 10.1038/sj.bjp.0707308. Epub 2007 May 29.
Within recent years, a paradigm shift from traditional receptor-specific studies to a cross-receptor view has taken place within pharmaceutical research to increase the efficiency of modern drug discovery. Receptors are no longer viewed as single entities but grouped into sets of related proteins or receptor families that are explored in a systematic manner. This interdisciplinary approach attempting to derive predictive links between the chemical structures of bioactive molecules and the receptors with which these molecules interact is referred to as chemogenomics. Insights from chemogenomics are used for the rational compilation of screening sets and for the rational design and synthesis of directed chemical libraries to accelerate drug discovery.
近年来，药物研究领域发生了范式转变，从传统的受体特异性研究转向交叉受体视角，以提高现代药物发现的效率。受体不再被视为单个实体，而是被归类为相关蛋白质组或受体家族，并以系统的方式进行探索。这种试图推导生物活性分子化学结构与这些分子相互作用的受体之间预测性联系的跨学科方法被称为化学基因组学。化学基因组学的见解被用于合理编纂筛选集以及合理设计和合成定向化学文库，以加速药物发现。
